ADMA Biologics Balance Sheet Health
Financial Health criteria checks 5/6
ADMA Biologics has a total shareholder equity of $153.7M and total debt of $130.8M, which brings its debt-to-equity ratio to 85.1%. Its total assets and total liabilities are $350.9M and $197.2M respectively. ADMA Biologics's EBIT is $47.1M making its interest coverage ratio 2.3. It has cash and short-term investments of $45.3M.
Key information
85.1%
Debt to equity ratio
US$130.85m
Debt
| Interest coverage ratio | 2.3x |
| Cash | US$45.33m |
| Equity | US$153.71m |
| Total liabilities | US$197.17m |
| Total assets | US$350.88m |
Recent financial health updates
Is ADMA Biologics (NASDAQ:ADMA) A Risky Investment?
Apr 04
We Think ADMA Biologics (NASDAQ:ADMA) Has A Fair Chunk Of Debt
Oct 25We Think ADMA Biologics (NASDAQ:ADMA) Has A Fair Chunk Of Debt
Jun 10ADMA Biologics (NASDAQ:ADMA) Is Carrying A Fair Bit Of Debt
Jun 01ADMA Biologics (NASDAQ:ADMA) Is Carrying A Fair Bit Of Debt
Dec 02Recent updates
Is ADMA Biologics, Inc. (NASDAQ:ADMA) Trading At A 43% Discount?
May 30ADMA Biologics, Inc. Just Beat EPS By 45%: Here's What Analysts Think Will Happen Next
May 13Giving ADMA Biologics A Well-Deserved 'Booyah'
May 12ADMA Biologics, Inc.'s (NASDAQ:ADMA) Prospects Need A Boost To Lift Shares
May 08Is ADMA Biologics (NASDAQ:ADMA) A Risky Investment?
Apr 04Rising Margins And Product Promise Drive ADMA Biologics Forward (Rating Upgrade)
Apr 03ADMA Biologics: On A Roll Entering 2024
Jan 19Is There An Opportunity With ADMA Biologics, Inc.'s (NASDAQ:ADMA) 50% Undervaluation?
Jan 09ADMA Biologics, Inc. (NASDAQ:ADMA) Surges 30% Yet Its Low P/S Is No Reason For Excitement
Jan 09We Think ADMA Biologics (NASDAQ:ADMA) Has A Fair Chunk Of Debt
Oct 25We Think ADMA Biologics (NASDAQ:ADMA) Has A Fair Chunk Of Debt
Jun 10The Market Doesn't Like What It Sees From ADMA Biologics, Inc.'s (NASDAQ:ADMA) Revenues Yet
May 12ADMA Biologics: Strong Growth Is Clearing The Path To Profitability
Aug 21ADMA Biologics GAAP EPS of -$0.07, revenue of $33.9M
Aug 10ADMA Biologics (NASDAQ:ADMA) Is Carrying A Fair Bit Of Debt
Jun 01ADMA Biologics: A Path To Profits Looks Clear
May 12ADMA: Pertinent Updates
Apr 18ADMA Biologics' 2021 Numbers Showed Continued Strong Execution
Mar 29ADMA Biologics: 2021 Was Tough
Jan 18ADMA Biologics (NASDAQ:ADMA) Is Carrying A Fair Bit Of Debt
Dec 02ADMA Biologics: Turning A Corner
Nov 20ADMA: Insiders Showing Their Cards
Nov 02ADMA Biologics: Recent Significant Developments And Their Implications For The Stock
Aug 22ADMA Biologics: Feeling Bullish After Encouraging Q2 Earnings Report
Aug 14Financial Position Analysis
Short Term Liabilities: ADMA's short term assets ($276.4M) exceed its short term liabilities ($53.1M).
Long Term Liabilities: ADMA's short term assets ($276.4M) exceed its long term liabilities ($144.1M).
Debt to Equity History and Analysis
Debt Level: ADMA's net debt to equity ratio (55.6%) is considered high.
Reducing Debt: ADMA's debt to equity ratio has reduced from 555.5% to 85.1% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable ADMA has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: ADMA is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 5.6% per year.